New Haven-based Trevi Therapeutics has named three new high-level leaders. “We are pleased to welcome Shashank Rohatagi, Farrell Simon, and Kathy Takaki to our management team as we move forward,” said Jennifer L. Good, Trevi’s president and CEO.
The company is focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.